R1 RCM has received a noncompliance notice from Nasdaq’s Listing Qualifications Department resulting from R1’s delay in filing its quarterly report on Form 10-Q for the third quarter of 2023. Nasdaq’s ...

Update 4:30pm: Updates shares, adds comment from R1 RCM holder. R1 RCM (NASDAQ:RCM) jumped 25% after New Mountain offered to buy the company for $13.75 a share in a cash. New Mountain also requested ...

MURRAY, Utah, June 17, 2024 (GLOBE NEWSWIRE) -- R1 RCM Inc. (RCM) (“R1” or the “Company”), a leading provider of technology-driven solutions that transform the patient experience and financial ...

R1 RCM has received an investment from venture capital firm Khosla Ventures to further its push into AI-powered healthcare revenue cycle transformation. Khosla Ventures is a leading backer of AI ...

New Mountain Capital is offering to buy out other investors in revenue cycle management giant R1 RCM for $13.75 a share in cash. The private equity firm’s offer represents a 24% premium to R1’s ...

MURRAY, Utah, Dec. 06, 2023 (GLOBE NEWSWIRE) -- R1 RCM Inc. (NASDAQ: RCM) (“R1”), a leading provider of technology-driven solutions that transform the patient experience and financial performance of ...

In a report released today, Daniel Grosslight from Citi downgraded R1 RCM (RCM – Research Report) to a Hold, with a price target of $14.30. Daniel Grosslight has given his Hold rating due to a ...

Add Yahoo as a preferred source to see more of our stories on Google. (Reuters) -R1 RCM said on Thursday private-equity firms TowerBrook Capital Partners and Clayton, Dubilier & Rice (CD&R) would ...

Voss Capital, LLC an investment management company, released its first-quarter 2024 investor letter. A copy of the letter can be downloaded here. Voss Capital’s funds, Voss Value Fund, LP, and the ...

MURRAY, Utah, Nov. 02, 2023 (GLOBE NEWSWIRE) -- R1 RCM Inc. (NASDAQ: RCM), a leading provider of technology-driven solutions that transform the patient experience and financial performance of ...

(Reuters) -R1 RCM said on Thursday private-equity firms TowerBrook Capital Partners and Clayton, Dubilier & Rice (CD&R) would acquire the healthcare technology company in a deal that values it at $8.9 ...